PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930090
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930090
Lutetium-177 Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of lutetium-177 (Lu-177) Market
The global lutetium-177 (Lu-177) market is witnessing rapid expansion due to the growing adoption of targeted radionuclide therapies in oncology. According to Fortune Business Insights, the lutetium-177 market size was valued at USD 2.73 billion in 2025 and is projected to grow to USD 3.43 billion in 2026. The market is expected to reach USD 14.7 billion by 2034, registering a strong CAGR of 19.95% during the 2026-2034 forecast period.
North America dominated the global lutetium-177 market with an 80.95% market share in 2025, driven by high cancer prevalence, robust reimbursement frameworks, and the presence of large-scale Lu-177 production facilities.
Market Overview
Lutetium-177 is a radioactive isotope widely used in targeted radionuclide therapy, particularly for treating prostate cancer and neuroendocrine tumors. It delivers beta radiation directly to cancer cells by binding to specific receptors such as prostate-specific membrane antigen (PSMA), thereby minimizing damage to surrounding healthy tissues. These clinical advantages have positioned Lu-177 as a critical component of precision oncology.
The rising incidence of cancer globally, increasing demand for targeted treatments, and strong research and development pipelines from leading pharmaceutical companies are accelerating market growth. Prominent players such as Novartis AG, Lantheus Holdings, Inc., and Telix Pharmaceuticals Limited are actively investing in clinical trials and product expansion.
Market Drivers
Rising Prevalence of Cancer
The increasing burden of cancer, particularly prostate cancer and neuroendocrine tumors, is a primary driver of the lutetium-177 market. Lu-177-based therapies offer improved therapeutic precision, making them highly suitable for advanced and metastatic cancers.
For instance, according to the American Cancer Society, 313,780 new prostate cancer cases were estimated in the U.S. in 2025, highlighting the growing patient pool requiring targeted therapies and supporting market expansion.
Strong Research and Development Activity
Extensive R&D efforts and late-stage clinical trials are further propelling market growth. In December 2023, Lantheus Holdings, Inc., in collaboration with POINT Biopharma, announced positive topline results from the Phase 3 SPLASH study evaluating 177Lu-PNT2002 for metastatic castration-resistant prostate cancer, reinforcing confidence in Lu-177-based treatments.
Market Restraints
Despite strong growth prospects, the market faces challenges due to the high cost of Lu-177 treatment, particularly in lower- and middle-income countries. Costs associated with radiopharmaceutical manufacturing, specialized facilities, regulatory compliance, and trained personnel significantly increase treatment expenses.
Additionally, limited nuclear medicine infrastructure and inadequate reimbursement policies in developing regions restrict widespread adoption.
Market Opportunities
Expansion of Clinical Applications
The increasing number of clinical trials exploring new therapeutic indications for Lu-177 presents significant growth opportunities. Regulatory approvals for new Lu-177 candidates and pediatric indications are expanding the addressable patient population.
For example, the U.S. FDA granted Rare Pediatric Disease Designation to Y-mAbs Therapeutics for 177Lu-omburtamab-DTPA, highlighting future growth potential beyond adult oncology.
Market Trends
Growth of Combination Therapies
The use of Lu-177 in combination with chemotherapy and immunotherapy is emerging as a key trend. Combination approaches enhance treatment efficacy, reduce resistance, and allow lower radiation doses. Pharmaceutical collaborations aimed at developing such therapies are gaining momentum.
Segmentation Analysis
By Drug
Based on drug type, the market is segmented into LUTATHERA, PLUVICTO, and others.
LUTATHERA (lutetium Lu 177 dotatate) held a dominant share in 2024 due to rising neuroendocrine tumor prevalence. PLUVICTO is expected to witness strong growth, supported by increasing prostate cancer cases and reimbursement approvals, such as Canada's public reimbursement decision in March 2025.
By Age Group
The adult segment dominated the market in 2024, driven by the high prevalence of prostate cancer among individuals aged 65 and above. The pediatric segment is expected to grow steadily due to regulatory approvals for pediatric use of Lu-177 therapies.
By Application
The prostate cancer segment accounted for the largest share in 2024, supported by increasing disease prevalence and product launches. The neuroendocrine tumors segment is also expected to grow notably due to rising incidence and ongoing R&D activities.
By End User
Hospitals dominated the market in 2024, owing to advanced infrastructure for handling radiopharmaceuticals and increasing collaborations with biotechnology companies. Specialty clinics and research institutes are also witnessing growing adoption.
Regional Insights
The North America lutetium-177 market was valued at USD 2.21 billion in 2025, driven by advanced healthcare infrastructure and strong reimbursement policies. The U.S. remains the largest contributor due to the presence of major manufacturers and production facilities.
Europe holds the second-largest share, supported by rising cancer cases and dedicated nuclear medicine centers. Asia Pacific is projected to be the fastest-growing region due to increasing cancer prevalence, expanding clinical trials, and growing investment in radiopharmaceutical research.
Competitive Landscape
The market is consolidated, with Novartis AG holding a significant share due to its robust product portfolio and regulatory approvals. Other key players include Telix Pharmaceuticals, Lantheus Holdings, Radiopharm Theranostics, and Curium, all actively expanding their Lu-177 pipelines.
Conclusion
The global lutetium-177 market, valued at USD 2.73 billion in 2025, is projected to grow to USD 3.43 billion in 2026 and reach USD 14.7 billion by 2034. The increasing prevalence of cancer, strong clinical pipelines, and rising adoption of targeted radionuclide therapy are expected to support sustained market growth over the forecast period.
Segmentation By Drug
- LUTATHERA (lutetium Lu 177 dotatate)
- PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
- Others
By Age Group
- Adults
- Pediatrics
By Application
- Neuroendocrine Tumor
- Prostate Cancer
- Others
By End-User
- Hospitals
- Specialty Clinics
- Others
By Region
- North America (By Drug, Age Group, Application, End-User, and Country)
- U.S.
- Canada
- Europe ( By Drug, Age Group, Application, End-User, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific ( By Drug, Age Group, Application, End-User, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
- Rest of the World ( By Drug, Age Group, Application, and End-User)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Key Diseases, By Key Countries/Regions, 2025
- 4.2. Pipeline Analysis, by Key Players
- 4.3. New Product Launches, by Key Players
- 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.5. Impact of COVID-19 on the Market
5. Global Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug
- 5.1.1. LUTATHERA (lutetium Lu 177 dotatate)
- 5.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
- 5.1.3. Others
- 5.2. Market Analysis, Insights and Forecast - By Age Group
- 5.2.1. Adults
- 5.2.2. Pediatrics
- 5.3. Market Analysis, Insights and Forecast - By Application
- 5.3.1. Neuroendocrine Tumors
- 5.3.2. Prostate Cancer
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - By End-User
- 5.4.1. Hospitals
- 5.4.2. Specialty Clinics
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast - Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Rest of the World
6. North America Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug
- 6.1.1. LUTATHERA (lutetium Lu 177 dotatate)
- 6.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
- 6.1.3. Others
- 6.2. Market Analysis, Insights and Forecast - By Age Group
- 6.2.1. Adults
- 6.2.2. Pediatrics
- 6.3. Market Analysis, Insights and Forecast - By Application
- 6.3.1. Neuroendocrine Tumors
- 6.3.2. Prostate Cancer
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast - By End-User
- 6.4.1. Hospitals
- 6.4.2. Specialty Clinics
- 6.4.3. Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug
- 7.1.1. LUTATHERA (lutetium Lu 177 dotatate)
- 7.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
- 7.1.3. Others
- 7.2. Market Analysis, Insights and Forecast - By Age Group
- 7.2.1. Adults
- 7.2.2. Pediatrics
- 7.3. Market Analysis, Insights and Forecast - By Application
- 7.3.1. Neuroendocrine Tumors
- 7.3.2. Prostate Cancer
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast - By End-User
- 7.4.1. Hospitals
- 7.4.2. Specialty Clinics
- 7.4.3. Others
- 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.5.1. Germany
- 7.5.2. U.K.
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug
- 8.1.1. LUTATHERA (lutetium Lu 177 dotatate)
- 8.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
- 8.1.3. Others
- 8.2. Market Analysis, Insights and Forecast - By Age Group
- 8.2.1. Adults
- 8.2.2. Pediatrics
- 8.3. Market Analysis, Insights and Forecast - By Application
- 8.3.1. Neuroendocrine Tumors
- 8.3.2. Prostate Cancer
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast - By End-User
- 8.4.1. Hospitals
- 8.4.2. Specialty Clinics
- 8.4.3. Others
- 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Rest of the World Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug
- 9.1.1. LUTATHERA (lutetium Lu 177 dotatate)
- 9.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
- 9.1.3. Others
- 9.2. Market Analysis, Insights and Forecast - By Age Group
- 9.2.1. Adults
- 9.2.2. Pediatrics
- 9.3. Market Analysis, Insights and Forecast - By Application
- 9.3.1. Neuroendocrine Tumors
- 9.3.2. Prostate Cancer
- 9.3.3. Others
- 9.4. Market Analysis, Insights and Forecast - By End-User
- 9.4.1. Hospitals
- 9.4.2. Specialty Clinics
- 9.4.3. Others
10. Competitive Analysis
- 10.1. Global Market Share Analysis (2025)
- 10.2. Company Profiles
- 10.2.1. Novartis AG
- 10.2.1.1. Overview
- 10.2.1.2. Products
- 10.2.1.3. SWOT Analysis
- 10.2.1.4. Recent Developments
- 10.2.1.5. Strategies
- 10.2.1.6. Financials (Based on Availability)
- 10.2.2. Telix Pharmaceuticals Limited
- 10.2.2.1. Overview
- 10.2.2.2. Products
- 10.2.2.3. SWOT Analysis
- 10.2.2.4. Recent Developments
- 10.2.2.5. Strategies
- 10.2.2.6. Financials (Based on Availability)
- 10.2.3. Ariceum Therapeutics
- 10.2.3.1. Overview
- 10.2.3.2. Products
- 10.2.3.3. SWOT Analysis
- 10.2.3.4. Recent Developments
- 10.2.3.5. Strategies
- 10.2.3.6. Financials (Based on Availability)
- 10.2.4. Radiopharm Theranostics Limited
- 10.2.4.1. Overview
- 10.2.4.2. Products
- 10.2.4.3. SWOT Analysis
- 10.2.4.4. Recent Developments
- 10.2.4.5. Strategies
- 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Lantheus Holdings, Inc.
- 10.2.5.1. Overview
- 10.2.5.2. Products
- 10.2.5.3. SWOT Analysis
- 10.2.5.4. Recent Developments
- 10.2.5.5. Strategies
- 10.2.5.6. Financials (Based on Availability)
- 10.2.6. Y-mAbs Therapeutics, Inc.
- 10.2.6.1. Overview
- 10.2.6.2. Products
- 10.2.6.3. SWOT Analysis
- 10.2.6.4. Recent Developments
- 10.2.6.5. Strategies
- 10.2.6.6. Financials (Based on Availability)
- 10.2.7. GLYTHERIX
- 10.2.7.1. Overview
- 10.2.7.2. Products
- 10.2.7.3. SWOT Analysis
- 10.2.7.4. Recent Developments
- 10.2.7.5. Strategies
- 10.2.7.6. Financials (Based on Availability)
- 10.2.8. Curium
- 10.2.8.1. Overview
- 10.2.8.2. Products
- 10.2.8.3. SWOT Analysis
- 10.2.8.4. Recent Developments
- 10.2.8.5. Strategies
- 10.2.8.6. Financials (Based on Availability)
- 10.2.1. Novartis AG
List of Tables
- Table 1: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 2: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 3: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 4: Global Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 5: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 6: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 7: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 8: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 9: North America Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 10: North America Lutetium-177 Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 11: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 12: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 13: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 14: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 15: Europe Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 16: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 17: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 18: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 19: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 20: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 22: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 23: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 24: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 25: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Lutetium-177 Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Lutetium-177 Market Value Share (%), by Drug, 2025 & 2034
- Figure 3: Global Lutetium-177 Market Value Share (%), by Age Group, 2025 & 2034
- Figure 4: Global Lutetium-177 Market Value Share (%), by Application, 2025 & 2034
- Figure 5: Global Lutetium-177 Market Value Share (%), by End-User, 2025 & 2034
- Figure 6: North America Lutetium-177 Market Value (USD billion), by Drug, 2025 & 2034
- Figure 7: North America Lutetium-177 Market Value Share (%), by Drug, 2025
- Figure 8: North America Lutetium-177 Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 9: North America Lutetium-177 Market Value Share (%), by Age Group, 2025
- Figure 10: North America Lutetium-177 Market Value (USD billion), by Application, 2025 & 2034
- Figure 11: North America Lutetium-177 Market Value Share (%), by Application, 2025
- Figure 12: North America Lutetium-177 Market Value (USD billion), by End-User, 2025 & 2034
- Figure 13: North America Lutetium-177 Market Value Share (%), by End-User, 2025
- Figure 14: North America Lutetium-177 Market Value (USD billion), By Country, 2025 & 2034
- Figure 15: North America Lutetium-177 Market Value Share (%), By Country, 2025
- Figure 16: Europe Lutetium-177 Market Value (USD billion), by Drug, 2025 & 2034
- Figure 17: Europe Lutetium-177 Market Value Share (%), by Drug, 2025
- Figure 18: Europe Lutetium-177 Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 19: Europe Lutetium-177 Market Value Share (%), by Age Group, 2025
- Figure 20: Europe Lutetium-177 Market Value (USD billion), by Application, 2025 & 2034
- Figure 21: Europe Lutetium-177 Market Value Share (%), by Application, 2025
- Figure 22: Europe Lutetium-177 Market Value (USD billion), by End-User, 2025 & 2034
- Figure 23: Europe Lutetium-177 Market Value Share (%), by End-User, 2025
- Figure 24: Europe Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 25: Europe Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2025
- Figure 26: Asia Pacific Lutetium-177 Market Value (USD billion), by Drug, 2025 & 2034
- Figure 27: Asia Pacific Lutetium-177 Market Value Share (%), by Drug, 2025
- Figure 28: Asia Pacific Lutetium-177 Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 29: Asia Pacific Lutetium-177 Market Value Share (%), by Age Group, 2025
- Figure 30: Asia Pacific Lutetium-177 Market Value (USD billion), by Application, 2025 & 2034
- Figure 31: Asia Pacific Lutetium-177 Market Value Share (%), by Application, 2025
- Figure 32: Asia Pacific Lutetium-177 Market Value (USD billion), by End-User, 2025 & 2034
- Figure 33: Asia Pacific Lutetium-177 Market Value Share (%), by End-User, 2025
- Figure 34: Asia Pacific Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 35: Asia Pacific Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2025
- Figure 36: Rest of the World Lutetium-177 Market Value (USD billion), by Drug, 2025 & 2034
- Figure 37: Rest of the World Lutetium-177 Market Value Share (%), by Drug, 2025
- Figure 38: Rest of the World Lutetium-177 Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 39: Rest of the World Lutetium-177 Market Value Share (%), by Age Group, 2025
- Figure 40: Rest of the World Lutetium-177 Market Value (USD billion), by Application, 2025 & 2034
- Figure 41: Rest of the World Lutetium-177 Market Value Share (%), by Application, 2025
- Figure 42: Rest of the World Lutetium-177 Market Value (USD billion), by End-User, 2025 & 2034
- Figure 43: Rest of the World Lutetium-177 Market Value Share (%), by End-User, 2025
- Figure 44: Rest of the World Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 45: Rest of the World Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2025
Figure 46: Global Lutetium-177 Market Share (%), By Company, 2025
